Market capitalization | $18.13m |
Enterprise Value | $20.47m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-45.10m |
Free cash flow (TTM) Free cash flow | $-42.63m |
Cash position | $18.21m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
2 Analysts have issued a Iterum Therapeutics Plc forecast:
2 Analysts have issued a Iterum Therapeutics Plc forecast:
Dec '23 | |
Current assets | 26 26 |
Fixed assets | 0.66 0.66 |
Total assets | 26 26 |
Dec '23 | |
Equity | -6.40 -6.40 |
Debt capital | 33 33 |
Total capital | 26 26 |
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Iterum Therapeutics Plc is a pharmaceutical company which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. It operates through the Ireland and Unites States geographical segments. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.
Head office | Ireland |
CEO | Corey Fishman |
Employees | 14 |
Founded | 2015 |
Website | www.iterumtx.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.